Scleroderma - Clinical and pathological advances

Best Practice and Research: Clinical Rheumatology

Volumn 18, Issue 3, 2004, Pages 271-290

  Denton, Christopher P ^a   Black, Carol M ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Fibrosis; Management; Organ based complications; Pulmonary hsdypertension; Scleroderma; Systemic sclerosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; EMOLLIENT AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; LOSARTAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC ACID DERIVATIVE; OXYGEN; PANCREAS ENZYME; PHOSPHODIESTERASE INHIBITOR; PROKINETIC AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTON PUMP INHIBITOR; SILDENAFIL; SPASMOLYTIC AGENT; STEROID; THYMOCYTE ANTIBODY; UNINDEXED DRUG; UNIPROST;

BIOMECHANICS; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG TARGETING; FUNCTIONAL DISEASE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INFLAMMATION; KIDNEY DISEASE; LUNG DISEASE; LUNG FIBROSIS; MEDICAL ASSESSMENT; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REFLUX ESOPHAGITIS; REVIEW; SCLERODERMA; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VALIDATION PROCESS; VASCULAR DISEASE;

COST OF ILLNESS; GASTROINTESTINAL TRACT; HUMANS; KIDNEY; LUNG; MYOCARDIUM; QUALITY OF LIFE; SCLERODERMA, SYSTEMIC; SKIN;

EID: 3242723418     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2004.03.001     Document Type: Review

References (77)

1. Denton C.P. Abraham D.J. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis Current Opinion in Rheumatology 13 2001 505-511
2. Ong V.H. Evans L.A. Shiwen X. et al Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse Arthritis and Rheumatism 48 2003 1979-1991
3. Mayes M.D. Endothelin and endothelin receptor antagonists in systemic rheumatic disease Arthritis and Rheumatism 48 2003 1190-1199
4. Takehara K. Hypothesis: pathogenesis of systemic sclerosis Journal of Rheumatology 30 2003 755-759
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Arthritis and Rheumatism 23 1980 581 590
6. Auzary C. Mouthon L. Soilleux M. et al Localized subcutaneous Nocardia farcinica abscess in a woman with overlap syndrome between systemic scleroderma and polymyositis Annales de Médecin Interne (Paris) 150 1999 582-584
7. LeRoy E.C. Medsger Jr. T.A. Criteria for the classification of early systemic sclerosis Journal of Rheumatology 28 2001 1573-1576
8. Poormoghim H. Lucas M. Fertig N. Medsger Jr. T.A. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients Arthritis and Rheumatism 43 2000 444-451
9. Marzano A.V. Menni S. Parodi A. et al Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases European Journal of Dermatology 13 2003 171-716
10. Tan F.K. Arnett F.C. Antohi S. et al Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases Journal of Immunology 163 1999 1066-1072
11. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases Archives of Internal Medicine 158 1998 595-600
12. Rajkumar V.S. Sundberg C. Abraham D.J. Rubin K. Black C.M. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis Arthritis and Rheumatism 42 1999 930-941
13. Rodnan G.P. Lipinski E. Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma Arthritis and Rheumatism 22 1979 130-140
14. Clements P. Lachenbruch P. Siebold J. et al Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis Journal of Rheumatology 22 1995 1281-1285
15. Silman A. Harrison M. Brennan P. Is it possible to reduce observer variability in skin score assessment of scleroderma? The ad hoc International Group on the Assessment of Disease Outcome in Scleroderma Journal of Rheumatology 22 1995 1277-1280
16. Falanga V. Bucalo B. Use of a durometer to assess skin hardness Journal of the American Academy of Dermatology 29 1993 47-51
17. Balbir-Gurman A. Denton C.P. Nichols B. et al Non-invasive measurement of biomechanical skin properties in systemic sclerosis Annals of the Rheumatic Diseases 61 2002 237-241
18. Knight L.R. Smeathers J.E. Isdale A.H. Helliwell P.S. Evaluating the cutaneous involvement in scleroderma: torsional stiffness revisited Rheumatology 40 2001 128-132
19. Scheja A. Akesson A. Comparison of high frequency (20 MHz) ultrasound and palpation for the assessment of skin involvement in systemic sclerosis (scleroderma) Clinical and Experimental Rheumatology 15 1997 283-288
20. Hesselstrand R. Westergren-Thorsson G. et al The association between changes in skin echogenicity and the fibroblast production of biglycan and versican in systemic sclerosis Clinical and Experimental Rheumatology 20 2002 301-308
21. Moore T.L. Lunt M. McManus B. Anderson M.E. Herrick A.L. Seventeen-point dermal ultrasound scoring system-a reliable measure of skin thickness in patients with systemic sclerosis Rheumatology 42 2003 1559-1563A
22. Poole J.L. Steen V.D. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis Arthritis Care and Research 4 1991 27-31
23. Steen V.D. Medsger Jr. T.A. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time Arthritis and Rheumatism 40 1997 1984-1991
24. Clements P.J. Wong W.K. Hurwitz E.L. et al The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial Arthritis and Rheumatism 44 2001 653-661
25. Silman A. Akesson A. Newman J. et al Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument Journal of Rheumatology 25 1998 79-83
26. Smyth A.E. MacGregor A.J. Mukerjee D. et al A cross-sectional comparison of three self-reported functional indices in scleroderma Rheumatology 42 2003 732-738
27. Merkel P.A. Herlyn K. Martin R.W. et al Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon Arthritis and Rheumatism 46 2002 2410-2420
28. Medsger Jr. T.A. Silman A.J. Steen V.D. et al A disease severity scale for systemic sclerosis: development and testing Journal of Rheumatology 26 1999 2159-2167
29. Valentini G. Bencivelli W. Bombardieri S. et al European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria Annals of the Rheumatic Diseases 62 2003 901-903
30. Valentini G. Della Rossa A. Bombardieri S. et al European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes Annals of the Rheumatic Diseases 60 2001 592-598
31. Della Rossa A. Valentini G. Bombardieri S. et al European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres Annals of the Rheumatic Diseases 60 2001 585-591
32. McHugh N.J. Distler O. Giacomelli R. Riemekasten G. Non organ based laboratory markers in systemic sclerosis Clinical and Experimental Rheumatology 21 2003 S32-S38
33. Hunzelmann N. Risteli J. Risteli L. et al Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma? British Journal of Dermatology 139 1998 1020-1025
34. Hill C.L. Nguyen A.M. Roder D. Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study Annals of the Rheumatic Diseases 62 2003 728-731
35. Hesselstrand R. Scheja A. Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients Annals of the Rheumatic Diseases 57 1998 682-686
36. Pearson J.E. Silman A.J. Risk of cancer in patients with scleroderma Annals of the Rheumatic Diseases 62 2003 697-699
37. Latsi P.I. Wells A.U. Evaluation and management of alveolitis and interstitial lung disease in scleroderma Current Opinion in Rheumatology 15 2003 748-755
38. Wells A.U. Hansell D.M. Haslam P.L. et al Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis American Journal of Respiratory and Critical Care Medicine 157 1998 1474-1482
39. Wells A.U. Rubens M.B. du Bois R.M. Hansell D.M. Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography European Respiratory Journal 10 1997 280-285
40. Bouros D. Wells A.U. Nicholson A.G. et al Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome American Journal of Respiratory and Critical Care Medicine 165 2002 1581-1586
41. Mukerjee D. St George D. et al Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach Annals of the Rheumatic Diseases 62 2003 1088-1093
42. MacGregor A.J. Canavan R. Knight C. et al Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival Rheumatology 40 2001 453-459
43. Koh E.T. Lee P. Gladman D.D. Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients British Journal of Rheumatology 35 1996 989-993
44. Kawut S.M. Taichman D.B. Archer-Chicko C.L. et al Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis Chest 123 2003 344-350
45. Steen V. Medsger Jr. T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement Arthritis and Rheumatism 48 2003 516-522
46. Denton C.P. Cailes J.B. Phillips G.D. et al Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis British Journal of Rheumatology 36 1997 239-243
47. Nagaya N. Nishikimi T. Uematsu M. et al Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension Circulation 102 2000 865-870
48. White B. Interstitial lung disease in scleroderma Rheumatic Disease Clinics of North America 29 2003 371-390
49. Mok M.Y. Tse H.F. Lau C.S. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost Lupus 8 1999 328-331
50. Rubin L.J. Mendoza J. Hood M. et al Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial Annals of Internal Medicine 112 1990 485-491
51. Barst R.J. Rubin L.J. Long W.A. et al comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group New England Journal of Medicine 334 1996 296-302
52. Badesch D.B. Tapson V.F. McGoon M.D. et al Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial Annals of Internal Medicine 132 2000 425-434
53. Simonneau G. Barst R.J. Galie N. et al Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial American Journal of Respiratory and Critical Care Medicine 165 2002 800-804
54. Olschewski H. Simonneau G. Galie N. et al Inhaled iloprost for severe pulmonary hypertension New England Journal of Medicine 347 2002 322-329
55. Channick R.N. Simonneau G. Sitbon O. et al Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2000 1119-1123
56. Rubin L.J. Badesch D.B. Barst R.J. et al Bosentan therapy for pulmonary arterial hypertension New England Journal of Medicine 346 2002 896-903
57. Denton C.P. Black C.M. 351 and 352 trial groups Long term benefit of bosentan therapy in scleroderma associated pulmonary hypertension Arthritis and Rheumatism 46 2003 (abstract)
58. Ghofrani H.A. Wiedemann R. Rose F. et al Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial Lancet 360 2002 895-900
59. Albert N.M. Hague K. Managing patients with primary pulmonary hypertension: prostacyclin therapy American Journal of Critical Care 6 1997 274-280
60. Coghlan J.G. Mukerjee D. The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology Current Opinion in Rheumatology 13 2001 495-499
61. Karwatowski S.P. Chronos N.A. Sinclair H. et al Effect of systemic sclerosis on left ventricular long-axis motion and left ventricular mass assessed by magnetic resonance Journal of Cardiovascular and Magnetic Resonance 2 2000 109-117
62. Binks M. Passweg J.R. Furst D. et al Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease Annals of the Rheumatic Diseases 60 2001 577-584
63. Farge D. Marolleau J.P. Zohar S. et al Intensification et Autogreffe dans les Maladies Auto Immunes Resistantes (ISAMAIR) Study Group. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study British Journal of Haematology 119 2002 726-739
64. Nageh T. Sherwood R.A. Harris B.M. Byrne J.A. Thomas M.R. Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention International Journal of Cardiology 92 2003 285-293
65. Steen V.D. Costantino J.P. Shapiro A.P. Medsger Jr. T.A. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors Annals of Internal Medicine 113 1990 352-357
66. Denton C.P. Sweny P. Abdulla A. Black C.M. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases British Journal of Rheumatology 33 1994 90-92
67. DeMarco P.J. Weisman M.H. Seibold J.R. et al Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial Arthritis and Rheumatism 46 2002 2983-2989
68. Steen V.D. Medsger Jr. T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis Arthritis and Rheumatism 41 1998 1613-1619
69. Della Bella S. Molteni M. Mocellin C. Fumagalli S. Bonara P. et al Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules Prostaglandins 65 2001 73-83
70. Scorza R. Rivolta R. Mascagni B. et al Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis Journal of Rheumatology 24 1997 1944-1948
71. Walker J.G. Ahern M.J. Smith M.D. et al Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment Internal Medicine Journal 33 2003 216-220
72. Chang Y.J. Spiera H. Renal transplantation in scleroderma Medicine (Baltimore) 78 1999 382-385
73. Kingdon E.J. Knight C.J. Dustan K. et al Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment Rheumatology (Oxford) 42 2003 26-33
74. Lock G. Holstege A. Lang B. Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis American Journal of Gastroenterology 92 1997 763-771
75. Matzel K.E. Stadelmaier U. Hohenfellner M. Gall F.P. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence Lancet 346 1995 1124-1127
76. Watson M. Hally R.J. McCue P.A. Varga J. Jimenez S.A. Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis Arthritis and Rheumatism 39 1996 341-346
77. Calamia K.T. Scolapio J.S. Viggiano T.R. Endoscopic YAG laser treatment of watermelon stomach (gastric antral vascular ectasia) in patients with systemic sclerosis Clinical and Experimental Rheumatology 18 2000 605-608